• 1
    Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:16931703.
  • 2
    Camidge DR, Bang Y, Kwak EL, et al. Efficacy and safety of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer: updated results from the molecularly defined cohort of this first-in-man phase I study. Lancet Oncol. 2012;13:10111019.
  • 3
    Kim D-W, Ahn M-J, Shi Y, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2012;30S. Abstract 7533.
  • 4
    Shaw AT, Kim DY, Nagakawa K, et al. Phase III study of crizotinib vs pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive NSCLC (PROFILE 1007) [abstract]. Ann Oncol. 2012;23( suppl 9):ix402. Abstract LBA1.
  • 5
    Ou S-HI, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6:942946.
  • 6
    Shaw AT, Camidge DR, Engelman JA, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement [abstract]. J Clin Oncol. 2012;30S. Abstract 7508.
  • 7
    Nickens D, Tan W, Wilner K, et al. Pharmacokinetic/pharmacodynamic evaluation of the concentration-QTc relationship of crizotinib (PF-02341066), an anaplastic lymphoma kinase and c-MET/hepatocyte growth factor receptor dual inhibitor administered orally to patients with advanced cancer [abstract 1673]. Poster presented at: 101st Annual Meeting of the American Association for Cancer Research; April 17-21,2010; Washington, DC.
  • 8
    Pfizer Inc.Xalkori prescribing information [package insert].Groton, CT:Pfizer Inc.;2011. Available at: Accessed October 11, 2011.
  • 9
    Ou S-HI, Azada M, Dy J, et al. Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib. J Thorac Oncol. 2011;6:21352137.
  • 10
    Tan W, Wilner KD, Bang Y, et al. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients [abstract]. J Clin Oncol. 2010;28S. Abstract 2596.
  • 11
    Weickhardt AJ, Rothman MS, Salian-Mehta S, et al. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012;118:53025309.